# GLP-1s and the kidneys · PepVault guides

Source: https://pepvault.app/guides/glp-1s-and-the-kidneys

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# GLP-1s and the kidneys: what FLOW showed, and the dehydration risk

Reviewed November 2026 17 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Ozempic is approved to slow kidney disease after the FLOW trial, yet every GLP-1 label warns of kidney injury from dehydration. Both sides, label by label.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 17
- **Questions:** 8
- **Compounds:** 2

## The short answer

GLP-1s cut both ways for the kidneys. In the FLOW trial, semaglutide 1 mg cut major kidney events, counted with heart deaths, by 24% in people with type 2 diabetes and kidney disease, and Ozempic is FDA-approved for that use. But Ozempic, Wegovy, Mounjaro and Zepbound all warn of sudden kidney injury, mostly after vomiting or diarrhoea dried someone out. Drinking enough is the labels' protection.

- FLOW: 18.7% on semaglutide 1 mg against 23.2% on placebo had a major kidney event or heart death over a median 3.4 years; Ozempic gained the kidney indication on January 28, 2025.
- In SELECT, people with obesity and heart disease but no diabetes had fewer kidney events on semaglutide 2.4 mg (1.8% against 2.2%).
- Tirzepatide has no kidney outcome trial yet; in the SURPASS-CVOT heart trial, kidney events came 23% less often than on dulaglutide (6.0% against 7.6%).
- Kidney injury was uncommon in the weight trials (Zepbound 0.5% against 0.2%); the labels tie most reported cases to dehydration from vomiting or diarrhoea, and Wegovy's says it came more often during dose steps.

Every number checked at its primary source · Nov 20, 2026 · [17 sources](https://pepvault.app/guides/glp-1s-and-the-kidneys#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** One finished phase 3 kidney outcome trial (FLOW, semaglutide 1 mg in type 2 diabetes with kidney disease) behind an FDA indication; prespecified kidney analyses of SELECT and a 24-week trial for semaglutide without diabetes; exploratory analyses of two diabetes trials (SURPASS-CVOT, SURPASS-4) and a review for tirzepatide, with no kidney outcome trial yet; the kidney-injury warning rests on postmarketing reports and low trial rates.

## Are GLP-1s good or bad for your kidneys?

Over years, the evidence points to good. Semaglutide is the only GLP-1 with a finished trial built to count kidney outcomes, and it slowed kidney disease[6](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-6). Over days, the risk is fluid loss. A GLP-1 (pepvault.app/glossary/glp-1; a drug that copies the gut hormone that slows the stomach and quiets appetite) can cause nausea, vomiting and diarrhoea, and a body that loses more water than it takes in sends less blood through the kidneys. Every label covered here carries the same warning for that reason[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1) [2](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-2) [3](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-3) [4](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-4).

Two kidney tests run through this page. **eGFR** (estimated glomerular filtration rate) is worked out from a blood test and says how much blood the kidneys filter each minute; under 15 counts as kidney failure[6](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-6). **UACR** (urine albumin-to-creatinine ratio) measures albumin, a protein that leaks into the urine when the kidney's filters are damaged.

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault's side-effect log records each symptom with its date, a severity from 1 to 5 and a note, beside the compound it belongs to, so you can show your prescriber which weeks brought it on.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What did the FLOW trial find?

FLOW enrolled 3,533 adults with type 2 diabetes and chronic kidney disease, with an eGFR of 25 to 75 and albumin in the urine, nearly all already on a standard kidney-protecting blood pressure drug[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1). Half took semaglutide 1 mg a week, half a placebo (pepvault.app/glossary/placebo; a dummy shot)[6](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-6). The trial was stopped early on the advice given at a planned interim check, after a median of 3.4 years[6](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-6).

| Outcome in FLOW | Semaglutide 1 mg (1,767) | Placebo (1,766) | Hazard ratio |
| --- | --- | --- | --- |
| Main composite: kidney failure, eGFR halved, or death from kidney or heart causes | 18.7% | 23.2% | 0.76 |
| eGFR fell by half or more, and stayed there | 9.3% | 12.1% | 0.73 |
| eGFR under 15 (the kidney failure range) | 5.2% | 6.2% | 0.80 |
| Started dialysis or had a transplant | 4.9% | 5.7% | 0.84 |
| Heart-related death | 7.0% | 9.6% | 0.71 |
| Death from any cause | 12.8% | 15.8% | 0.80 |

Rows from the Ozempic label's Table 10[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1). A hazard ratio of 0.76 means the event came 24% less often over time. The kidney failure and dialysis rows, taken alone, had confidence intervals that crossed 1; the kidney-only composite was lower on semaglutide (hazard ratio 0.79)[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1) [6](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-6).

The slower decline is the part a person feels over years: eGFR fell 1.16 points a year less on semaglutide[6](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-6). Serious adverse events were fewer on the drug, 49.6% against 53.8%[6](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-6), and the label lists no new serious reaction from the trial[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1). One open question: among the 550 people already taking an SGLT2 inhibitor, the other main kidney drug class, the benefit did not show (41 against 38 events), and the authors, who call the kidney results consistent in both groups, note the subgroup was too small to detect a smaller benefit[7](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-7).

On January 28, 2025 the FDA approved Ozempic to reduce the risk of sustained eGFR decline, end-stage kidney disease and heart-related death in adults with type 2 diabetes and chronic kidney disease[5](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-5). For that use the label sets the lasting dose at 1 mg a week, reached after at least four weeks on 0.5 mg[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1). The FLOW study page (pepvault.app/research/semaglutide-flow-2024) has the full design.

## Does semaglutide protect the kidneys without diabetes?

The trials point that way, though no label claims it yet. SELECT (pepvault.app/research/semaglutide-select-2024) gave semaglutide 2.4 mg, the Wegovy dose, to 17,604 adults with overweight or obesity and heart disease but no diabetes. A combined kidney outcome, which counted new heavy albumin leaks as well as kidney failure and halved eGFR, came in 1.8% on the drug against 2.2% on placebo (hazard ratio 0.78), and at week 104 eGFR sat 0.75 points higher on the drug, 2.19 points in people who started below 60[8](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-8).

In the smaller SMART trial, 101 adults with kidney disease, a BMI of 27 or more and no diabetes saw albumin in the urine fall 52.1% against placebo after 24 weeks of semaglutide 2.4 mg[10](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-10). A 2026 analysis that pooled FLOW, SELECT and the oral-semaglutide trial SOUL, 30,787 people in all, found 16% fewer of the same combined kidney and heart-death outcome FLOW used (hazard ratio 0.84)[9](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-9). FLOW and the pooled analysis were funded by Novo Nordisk, which makes semaglutide[6](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-6) [9](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-9).

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Titration](https://pepvault.app/glossary/titration)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Adverse reaction](https://pepvault.app/glossary/adverse-reaction)
- [Double-blind](https://pepvault.app/glossary/double-blind)
- [Open-label](https://pepvault.app/glossary/open-label)
- [Confidence interval](https://pepvault.app/glossary/confidence-interval)

## What is known for tirzepatide (Mounjaro and Zepbound)?

Less, and nothing on the label yet. No trial has yet had kidney failure or dialysis as its main result for tirzepatide, and neither label carries a kidney use[3](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-3) [4](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-4). The largest signal is SURPASS-CVOT, a double-blind heart trial in 13,165 people with type 2 diabetes and heart disease: over a median 4 years, a combined kidney outcome came 23% less often on tirzepatide than on dulaglutide (Trulicity), 6.0% against 7.6% (hazard ratio 0.77), mostly through fewer new heavy albumin leaks[17](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-17). An earlier look back at SURPASS-4, an open-label trial in 2,002 people, most with normal kidney function, found eGFR falling 1.4 points a year on tirzepatide against 3.6 on insulin glargine[12](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-12). Both are exploratory analyses of trials built for other questions, so they suggest rather than prove.

A 2026 review of ten tirzepatide trials found albumin lowered against insulin, no clear effect on eGFR, and called for trials built around kidney outcomes[13](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-13). Lilly's TREASURE-CKD, a phase 2 trial in 134 people with overweight or obesity and kidney disease whose main measure is fat inside the kidney's hollow centre (renal sinus fat) on MRI, finished in July 2026; no results were posted on ClinicalTrials.gov as of November 2026[14](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-14).

## Can a GLP-1 cause kidney damage?

Yes, through dehydration, and the labels say so in nearly the same words. Ozempic's reads: "There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea"[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1). Acute kidney injury means the kidneys' filtering drops over hours or days. In the trials it was uncommon:

| Label | Kidney use on the label | Kidney injury in its trials | Dose change for kidney disease |
| --- | --- | --- | --- |
| Ozempic (semaglutide) | Yes: type 2 diabetes with kidney disease | No trial rate given; postmarketing reports | None recommended |
| Wegovy (semaglutide) | No | 0.4 against 0.2 cases per 100 patient-years (7 against 4 people), weight trials | None listed; drug levels unchanged at eGFR 30 to 89 |
| Mounjaro (tirzepatide) | No | No trial rate given; postmarketing reports | None recommended |
| Zepbound (tirzepatide) | No | 0.5% against 0.2%, SURMOUNT-1 and -2, up to 72 weeks | None recommended |

From each label's warnings (section 5), adverse reactions (6.1 and 6.2), kidney impairment (8.6) and pharmacokinetics (12.3)[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1) [2](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-2) [3](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-3) [4](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-4). Rates from different trials are not a head-to-head comparison. Each brand page has the rest of its label: Ozempic (pepvault.app/drugs/ozempic), Wegovy (pepvault.app/drugs/wegovy), Mounjaro (pepvault.app/drugs/mounjaro) and Zepbound (pepvault.app/drugs/zepbound).

Wegovy's label adds who is most exposed: kidney side effects were more common in people who already had reduced kidney function, and occurred more often during dose titration[2](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-2). Kidney disease does not change the dose on the Ozempic, Mounjaro or Zepbound labels, because drug levels stay the same down to kidney failure[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1) [3](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-3) [4](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-4); what changes is the watching. Whether a GLP-1 fits a person with kidney disease, and which, is the prescriber's decision, often with a kidney specialist.

## When is the dehydration risk highest, and what helps?

In the first weeks and after each dose step. All four labels tell prescribers to check kidney function in people with stomach side effects that could dry them out, "especially during dosage initiation and escalation"[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1) [2](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-2) [3](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-3) [4](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-4), and the Ozempic label notes that most nausea, vomiting and diarrhoea came during dose escalation[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1) (the full list: pepvault.app/peptides/semaglutide/side-effects). The patient guides give the plan in plain words: "It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away"[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1) [2](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-2) [3](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-3) [4](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-4). On a bad stomach day that looks like this:

1. Keep fluids going in small sips through the day, since a full glass on a queasy stomach often comes back up.
2. Notice how much you are passing: much less urine than usual is one of the signs of kidney trouble[15](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-15).
3. Write down what happened and when, so the pattern is clear if it lasts.
4. Call your prescriber right away if the vomiting or diarrhoea does not go away[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1) [2](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-2) [3](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-3) [4](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-4).

<!--promo-->

PepVault's side-effect log records each symptom with its date, a severity from 1 to 5 and a note, beside the compound it belongs to, so you can show your prescriber which weeks brought it on. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-glp-1s-and-the-kidneys-inline&mt=8)

<!--/promo-->

**Commonly reported:** people on a GLP-1 often say they drink less without noticing, because they eat less and the drinks that came with meals go too; many find a bottle kept in sight easier than remembering to drink.

## What does kidney pain on a GLP-1 mean?

None of the four labels lists kidney pain as a side effect[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1) [2](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-2) [3](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-3) [4](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-4). Pain in the side or back between the ribs and hip, called flank pain, has two kidney causes worth knowing. One is a kidney stone, which brings sharp pain in the back, side, lower belly or groin, sometimes with blood in the urine[16](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-16); in SELECT, stones were reported in 1.2% on Wegovy against 0.8% on placebo[2](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-2). The other is acute kidney injury itself, where flank pain can come with little or no urine and swelling in the legs or ankles[15](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-15). Ordinary back pain from muscles is far more common than either.

**When to get help** Sharp side or back pain, blood in the urine, very little urine, or vomiting and diarrhoea you cannot keep up with are reasons to contact your prescriber the same day[1](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-1) [15](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-15) [16](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-16).

## Will losing weight change your eGFR result?

Probably not much. eGFR is usually worked out from creatinine, a waste product of muscle, so doctors have asked whether losing muscle on a GLP-1 makes the kidneys look better than they are. In SMART, people lost 9.1 kg against placebo, and the changes in weight, lean mass and fat mass did not track the changes in eGFR, whether estimated from creatinine, from cystatin C (a second marker not made by muscle) or measured directly[11](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-11). The authors concluded that a 10% weight loss on semaglutide does not distort the estimate[11](https://pepvault.app/guides/glp-1s-and-the-kidneys#source-11).

<!--promo-->

PepVault's Bloodwork page keeps creatinine and eGFR by date, and your weigh-ins sit on their own chart, so each result your prescriber orders lines up with the months of treatment it came from. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-glp-1s-and-the-kidneys-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Ozempic (semaglutide) injection, prescribing information and Medication Guide (§1, §2.2, §5.6, §6.1, §8.6, §14.3 and Table 10). Novo Nordisk. DailyMed, SPL version 20, effective June 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
2. Wegovy (semaglutide) injection and tablets, prescribing information and Medication Guide (§5.5, §6.1, §12.3). Novo Nordisk. DailyMed, SPL version 19, June 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
3. Mounjaro (tirzepatide) injection, prescribing information and Medication Guide (§1, §5.5, §6.2, §8.6). Eli Lilly and Company. DailyMed, SPL version 40, August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
4. Zepbound (tirzepatide) injection, prescribing information and Medication Guide (§1, §5.3, §6.1, §8.6). Eli Lilly and Company. DailyMed, SPL version 40, revised August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
5. US FDA. Supplement approval letter, NDA 209637/S-025 (Ozempic): new indication to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. January 28, 2025. [accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/209637Orig1s025ltr.pdf)
6. Perkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. [PubMed 38785209](https://pubmed.ncbi.nlm.nih.gov/38785209/)
7. Mann JFE et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849-2856. [PubMed 38914124](https://pubmed.ncbi.nlm.nih.gov/38914124/)
8. Colhoun HM et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058-2066. [PubMed 38796653](https://pubmed.ncbi.nlm.nih.gov/38796653/)
9. Mann JFE et al. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. Lancet Diabetes Endocrinol. 2026;14(10):818-830. [PubMed 42567173](https://pubmed.ncbi.nlm.nih.gov/42567173/)
10. Apperloo EM et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial (SMART). Nat Med. 2025;31(1):278-285. [PubMed 39455729](https://pubmed.ncbi.nlm.nih.gov/39455729/)
11. Heerspink HJL et al. Effects of semaglutide on body composition and GFR: a prespecified analysis of the SMART trial. Clin J Am Soc Nephrol. 2026;21(7):1149-1158. [PubMed 42308057](https://pubmed.ncbi.nlm.nih.gov/42308057/)
12. Heerspink HJL et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774-785. [PubMed 36152639](https://pubmed.ncbi.nlm.nih.gov/36152639/)
13. Li S et al. Kidney effects of tirzepatide across albuminuria, filtration markers, and clinical outcomes: a parent-trial-level systematic review and meta-analysis. Diabetes Res Clin Pract. 2026 (online November 13). [PubMed 43025465](https://pubmed.ncbi.nlm.nih.gov/43025465/)
14. ClinicalTrials.gov. TREASURE-CKD: tirzepatide in overweight or obesity and chronic kidney disease with or without type 2 diabetes (NCT05536804). Eli Lilly and Company. Record updated September 2026. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05536804)
15. MedlinePlus (US National Library of Medicine). Acute kidney failure. Reviewed April 30, 2026. [medlineplus.gov](https://medlineplus.gov/ency/article/000501.htm)
16. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Symptoms and causes of kidney stones. [niddk.nih.gov](https://www.niddk.nih.gov/health-information/urologic-diseases/kidney-stones/symptoms-causes)
17. Zoungas S et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Lancet Diabetes Endocrinol. 2026;14(7):544-557. [PubMed 42114520](https://pubmed.ncbi.nlm.nih.gov/42114520/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)

None of the four labels mentions drinking. Where alcohol matters on Ozempic, Wegovy, Mounjaro or Zepbound, and what the alcohol trials of semaglutide found.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)

## Related guides

- Guide · GLP-1s

  ### [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)

  Ozempic and Wegovy side effects from the labels' trials, drug against placebo: nausea and the rest, when they start, how many days they last, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)

  Mounjaro and Zepbound side effects at 5, 10 and 15 mg against placebo, from the labels' trial tables: when they show up, how many stopped, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)

  Semaglutide vs tirzepatide side effects in the same trials: nausea, vomiting, reflux, hair loss and injection-site rates side by side, and how many stopped.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Titration](https://pepvault.app/glossary/titration)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Adverse reaction](https://pepvault.app/glossary/adverse-reaction)
- [Double-blind](https://pepvault.app/glossary/double-blind)
- [Open-label](https://pepvault.app/glossary/open-label)
- [Confidence interval](https://pepvault.app/glossary/confidence-interval)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
